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Abstract
Background and Objective: The patient package insert is an important source of drug information. The aim of this study 
was to evaluate and compare the PPI of the anti-infective agents manufactured in Palestine with the imported equivalents. 
Method: The selection criteria generated 15 different anti-infective agents available as 36 locally manufactured products and 
15 imported equivalents. The design of the patient package insert was evaluated in terms of the number of words used in 
eight main headings and the presence or absence of certain information regarding nine statements. Results: Inserts of 
locally manufactured products have significantly fewer words than those of imported products with respect to warnings, 
dosage and administration, and side effects. The most significant difference was found in the warnings. Moreover, differences 
were found between inserts of local and imported products in terms of the presence of the nine informative statements. 
Locally manufactured products did not mention inactive ingredients, clinical pharmacology or date of last revision, but all of 
them provided information on the use of the drug during pregnancy and lactation and on the duration of therapy. However, in 
general they provided less information than the imported equivalents. Conclusion: Palestinian authorities and local 
manufacturers should implement appropriate measures to regulate the quality and quantity of information in the patient 
package insert of locally produced anti-infective agents. PPI improvement will better direct health practices to the benefit of 
the patients.
Key words: patient package insert, evaluation, Palestine, drug information. 
 
Introduction
The patient package insert (PPI) is important for 
providing essential drug information for patients taking 
over-the-counter as well as prescription-only medications. 
In developing countries, the PPI is considered an 
important source of drug information for health-care 
providers as well, because of a limited ability to access up-
to-date information about drugs. In addition, studies have 
shown that the PPI helps bridge the information gap 
between health care providers and patients and enhances 
patients’ knowledge about medications [1,2]. The quality 
and quantity of information available in the PPI has been 
shown to influence patients’ compliance and satisfaction 
[3,4]. There are also indications that patients who read 
the PPI are more likely to follow the instructions, 
especially if the information in the PPI agrees with the 
instructions of the physician and/or pharmacist [5]. A 
study carried out in Denmark found that patients may be 
confused by inconsistent information in PPI, which leads 
to reduced compliance [6]. 
 
The design and the amount of information in the PPI 
are usually regulated by the legislative health authorities. 
The PPI should increase patient's awareness of 
medication-related issues, contribute to the safe and 
correct use of the medication, and help in the success of 
the treatment plan. The European Directive 2001/83/EC of 
November 2001 requires stipulates that in all European 
Union member states every drug should include an easily 
legible and clearly comprehensible package insert [7]. The 
European Commission provides guidelines for the contents 
of package inserts, including style and terminology [8,9]. 
In comparison to Europe, package inserts in the USA focus 
considerably more on medical specialists. American 
package inserts frequently feature smaller font and many 
technical terms and consist of up to six A4 pages [10,11]. 
Despite all efforts, PPI are still criticized in USA, many 
European countries [12], and Australia [13,14]. For 
example, it was reported that decreased compliance was 
found in patients who felt frightened after they had read 
the package insert [13]. Some experts have suggested 
that the PPI for drugs intended for children or pregnant 
women should include symbols and special features [15]. 
 
In Palestine, five local pharmaceutical companies 
produce about 1000 of the different medical products on 
the Palestinian market. Besides the locally manufactured 
medical products, many imported drugs are registered in 
the Palestinian market. The Palestinian Ministry of Health 
(MOH) recommends that all marketed medications be 
supplied with a PPI that is written in both Arabic and 
English, but there are no regulations regarding the quality 
or the quantity of the information, design and wording of 
the PPI.  
 
In this study we aimed to evaluate and compare the PPI 
contents of a group of selected anti-infective medications 
manufactured locally to the imported equivalents in the 
Palestinian market.  
 
Materials & Methods 
Inclusion Criteria 
Anti-infective agents were selected for study because 
they are commonly utilized and because infectious 
diseases are one of the most common causes of mortality 
in Palestine [16]. The inclusion criteria were as follows: (i) 
manufactured by at least two local pharmaceutical 
companies; (ii) have an imported equivalent; (iii) available 
in oral solid form; (iv) registered in the department of 
pharmacy at the Palestinian MOH; (v) available in the local 
market. Based on these criteria, 15 different anti-infective 
agents were included in this study: amoxicillin, 
amoxicillin/clavulanic acid, azithromycin, clarithromycin, 
metronidazole, terbinafin, ketoconazole, 
trimethoprim/sulfamethoxazole, cephalexin, cefuroxime, 
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mebendazole, doxycycline, ofloxacin, ciprofloxacin and 
fluconazole. The imported products selected in this study 
were the most popular equivalents that are manufactured 
outside the Palestinian authority areas. The popularity of a 
certain imported product was judged through a phone 
survey of 100 randomly selected community pharmacies in 
Palestine. In this survey, the pharmacists were asked to 
state the most commonly dispensed imported 
equivalent(s) for each of the studied agents.  
 
Evaluation and Assessment of the PPI 
The PPIs were initially evaluated according to the 
general design and quantitatively evaluated by two 
methods. The first was a simple word count of eight major 
headings: description, indications, contraindications, 
warnings, drug interactions, side effects, dosage and 
administration, and storage. The “warning” heading 
included both the caution and precaution headings. The 
words under each of the eight tested headings were 
counted manually.  
 
The second method of evaluation was carried out by 
using a scoring method for the presence of information on 
the following nine statements in the PPI: inactive 
ingredients, therapeutic class, clinical pharmacology, use 
during pregnancy and lactation, overdose, missed doses, 
duration of therapy, instructions not to consume after the 
expiration date, and the date of last revision. Presence of 
the information was scored as 1 and its absence as 0. The 
total score was calculated for each anti-infective agent. 
The percent score was calculated as a percentage of the 
possible maximal score for each local company as well as 
for the imported products.  
 
All data were entered into the statistical package for 
social sciences (SPSS) version 13. Mean score and mean 
word count was calculated for locally produced and for 
imported anti-infective agents. Statistical comparison was 
carried out using Student’s t-test.  
 
Results
General evaluation of the PPI 
The selected anti-infective agents were available in the 
Palestinian market as 36 local and 15 imported products 
(Table 1). The 36 local products are produced by four 
pharmaceutical companies designated as A (4 products), B 
(8 products), C (10 products), and D (14 products). The 
15 most popular imported anti-infective agents belong 
mainly to American and European companies (Table 1).  
 
All the inserts of all local and imported products were 
printed in both Arabic and English. In the local products, 
Arabic was on one side of the insert and English on the 
other. In contrast, most of the imported products had 
both languages on the same side. Inserts of locally 
manufactured products used smaller font than those of 
the corresponding imported products. 
  
The design of the inserts was also evaluated. The 
criteria used to assess design included size of the leaflet, 
text font size, and size and colour of headings. The overall 
design was different from one local company to another 
and even between different medications produced by the 
same company. With the exception of one local company, 
the headings in all local inserts were printed in black. In 
addition, the inserts of the local products differ from those 
of the imported equivalents in the order and terminology 
used for some headings.   
 
Word count 
We compared the word counts of the eight headings in 
the PPI of local and imported products. Significant 
differences in word count were found between the local 
and the imported products in the headings “warnings”, 
“side effects”, and “dosage and administration” with P 
values of 0.008, 0.016, and 0.024, respectively (Table 
2A,B). The word counts in table 2 were analyzed vertically 
and horizontally. The mean word counts for the 
“warnings” heading was 64.7 words in all local inserts 
combined and 167.7 words in all imported products 
combined, which is a 2.5-fold difference. Similar findings 
were observed in the “side effects” and “dosage and 
administration” headings (table 2). 
We also counted all words in each insert. With the 
exception of azithromycin, the total number of words in 
the eight tested headings was greater in the imported 
than in the local products (P= 0.01). The imported 
amoxicillin/clavulanic acid, terbinafin, ofloxacin, and 
cephalexin inserts had three- to fourfold more words than 
their local equivalents (Table 2A,B). Amoxicillin/clavulanic 
acid had the highest word count compared to the other 
drugs, but the imported product had 2989 words whereas 
the local product had only 582 words.  
 
Analysis of scores 
All inserts were also evaluated using the scoring 
method. The total score was 65.4 for the locally 
manufactured anti-infective agents and 81 for the 
imported equivalents (P= 0.02) (Table 3). None of the 
inserts achieved a full score. None of the local products 
had information on “inactive ingredients,” “clinical 
pharmacology” and “date of last revision,” whereas one 
third to one half of the imported products provided this 
type of information (Table 4). By contrast, all inserts 
contained instructions about use during pregnancy and 
lactation, overdose and duration of therapy (Table 4). 
However, the information concerning pregnancy and 
lactation in the local products was given under different 
headings, such as “contraindications,” “warnings” or 
“precautions,” or otherwise stated separately as follows: 
“inform your physician if you are pregnant or 
breastfeeding.” In addition, local products differed from 
imported products in the amount of information. Local 
products did not explain whether that can be used during 
pregnancy. In contrast, the imported products provide 
detailed information for both patients and health-care 
providers on the use of the medication during pregnancy 
and lactation. The pattern was similar for the statement 
pertaining to “overdose” and its consequences and first 
aid. “Go to the hospital in case of overdose”, and/or “do 
not induce vomiting” are the most common instructions 
found in the inserts of most local anti-infective agents. In 
contrast, inserts of imported products mentioned in details 
the effects expected from overdose and the proper 
emergency treatment. Regarding the “duration of 
treatment”, most inserts of local products state: “duration 
is as directed by the physician,” or “do not stop the 
medication without informing the physician.” By contrast, 
most imported products informed patients about how long 
the medication should be taken. 
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Inserts of imported cefuroxime, amoxicillin/clavulanic 
acid and metronidazole have the highest total score on the 
nine statements (Table 3). For the local products, 
amoxicillin/clavulanic acid has the highest score (5.5; 
Table 3). Among the four local pharmaceutical companies, 
the highest percent score (percent of the maximal score) 
was 51.4% and the lowest was 8.4%, compared to 60% 
for the imported pharmaceutical companies combined 
(Table 4).  
 
Discussion
We found significant differences in the quantity and 
quality of information in the inserts of locally produced 
compared to imported anti-infective medications. Although 
the word counts for the “indications” were not significantly 
different, there were differences in the quality of the 
information. Most of the local anti-infective agents 
mentioned the “indications” in general terms: “for the 
treatment of infections”. However, in the imported 
products, the “indications” heading included, in most of 
the cases, the sites and types of infections and in a few 
cases the name of susceptible micro-organisms. 
Differences between inserts of local and imported products 
were also found in statements regarding inactive 
ingredients, clinical pharmacology and date of last 
revision. It is important to list the inactive ingredients, 
such as sodium salts or artificial sweeteners, for the sake 
of patients with certain types of diseases or allergies. Not 
mentioning the date of last revision of the insert might 
negatively influence the patient’s and physician’s trust in 
the product. The differences between the local companies 
in the amount and type of information in the insert 
indicates that there is no governmental supervision over 
locally produced anti-infective agents, and probably other 
drugs as well, and that regulation is required to ensure 
that patients are provided sufficient information. 
Physicians and pharmacists who depend on locally written 
PPI as a source of drug information may not be able to 
provide good patient counselling and to obtain up-to-date 
information. For example, use of medications during 
pregnancy and lactation was not fully explained in inserts 
of local anti-infective products. Lack of detailed 
information about overdose makes health care providers 
and/or the general public unable to make the best 
decisions in case of poisoning. Early management of 
poisoning is important for good prognosis, and it cuts 
down on hospital visits and medical expenditure. 
 
Inadequate information in the PPI has been reported by 
authors in different countries. In a study carried out in 
Saudi Arabia, the authors found that there was substantial 
disagreement in information between generic package 
inserts and the British National Formulary and the package 
inserts of the brand products marketed in Saudi Arabia 
[17]. In another study of non-steroidal anti-inflammatory 
agents marketed in Saudi Arabia, the authors showed that 
inserts of Saudi-marketed products generally conveyed 
limited and incomplete information compared to their 
counterparts marketed in USA [18]. In the USA, it was 
shown that PPI do not fully meet the federal regulations 
[19]. A European study found substantial disagreement in 
the materials available to prescribers and patients in 
different countries [20]. A study in Perugia found that all 
people in the study complained that the print size used in 
the PPI is too small. Furthermore, the study found that the 
surveyed people would appreciate a more detailed 
package leaflet [21].     
 
A recent study carried out in Germany found that 
reading PPI might have less impact than assumed and 
that they are read selectively [22]. The authors concluded 
that personal recommendation from a physician or 
pharmacist is more helpful and more willingly accepted 
than information in PPI [22]. In the USA and Australia, 
pharmacy systems use computer-generated labels as a 
method of leaflet delivery. In contrast to package inserts, 
the computer-generated leaflets can be personalized and 
thus irrelevant information can be omitted and only age-
specific information included, leading to a shorter but 
more relevant leaflet. Another major advantage of 
electronically generated leaflets is that they can be 
instantly updated. Introduction of a computerized system 
for labeling and dispensing of medications in Palestine 
would be beneficial, but that requires the introduction of 
automation and internet services to local community 
pharmacies beforehand. 
 
In conclusion, there is a significant difference in the 
quantity and quality of information provided in the PPI of 
locally and imported anti-infective agents in Palestine. 
Experts in the Palestinian MOH need to review and 
approve the PPI content, to fulfill its role in health-care. 
 
Table 1 Anti-infective agents available in the Palestinian market 
that was included in the study. 
Amox/Clav = amoxicillin/ clavulanic acid  
Trim/Sulfa = Trimethoprim/sulfamethoxazole   
  
 
 
 
Anti-infective 
agent
Local products 
Most popular 
imported
equivalents 
Amoxicillin 
Amoxitid®, 
Moxypharm®, 
Amoxicare® 
Moxypen® 
Amox/ Clav 
Ogmin®, 
Clamoxin® 
Curam® 
Azithromycin 
Azimex®, 
Zitrocin®, 
Azicare® 
Azenil® 
Doxycycline 
Doxypharm®, 
Doxal®, Doxacin® 
Doxylin® 
Trim/ Sulfa 
Pathoprim®, 
Sulprim®, 
Sulfaprim® 
Resprim® 
Ofloxacin Ultracin®,  Taricin® Oflodex  ® 
Cefuroxime Zinex®,  Zinaxim®  Zinnat® 
Ciprofloxacin 
Ciproxx®, 
Ciprocare®, 
Floxin® 
Ciprofloxacin teva® 
Cephalexin 
Cefacare®, 
Cefalex®, Jeflex® 
Keflex® 
Metronidazole 
Entogyl®, 
Metrozole® 
Flagyl® 
Fluconazole Dican®,  Flucan®  Trican® 
Ketoconazole 
Orazole®, 
Ketoral® 
Nizoral® 
Mebendazole 
Vermacare®, 
Vermazole® 
Vermox® 
Clarithromycin 
Klaricare®, 
Laricid® 
Klacid® 
Terbinafin 
Lamirase®, 
Tanasil® 
Lamisil® 
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Table 2 A and B:  Word counts and statistical analysis 
A. Word counts of the major eight headings in the patient package inserts of the locally produced and imported anti-infective agents
Variable
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Amoxicillin
Loc.  
Imp.  
10.3  
8  
10.3  
0  
41.3  
24  
60.6  
70  
56  
57  
115.3  
131  
64  
82  
62.6  
59  
420.4  
431  
Amox/ Clav
Loc.  
Imp.  
16  
29  
10.5  
266  
32.5  
255  
45.5  
299  
87  
213  
196  
949  
141.5  
863  
53.5  
115  
582.5  
2989  
Azithromycin
Loc.  
Imp.  
7.3  
6  
29.7  
13  
16  
39  
53.3  
32  
61.7  
54  
118.7  
105  
87  
68  
43.6  
72  
417.3  
389  
Doxycyclin
Loc.  
Imp.  
11  
9  
20.5  
48  
13  
15  
72.7  
111  
37.3  
49  
74  
183  
43.3  
110  
23.6  
48  
295.4  
573  
Trim/ Sulfa
Loc.  
Imp.  
9.3  
9  
20.7  
4  
8  
32  
41.3  
188  
91.3  
55  
82.3  
129  
90.5  
114  
36.5  
60  
379.9  
591  
Ofloxacin
Loc.  
Imp.  
6  
6  
32  
40  
21.5  
65  
46  
123  
53.5  
122  
43.5  
198  
63  
439  
22.5  
47  
288  
1040  
Cefuroxime
Loc  
Imp  
10.5  
22  
11.5  
190  
14.5  
7  
60.5  
241  
83.5  
77  
190.5  
292  
108  
307  
46  
4  
525  
1140  
Ciprofloxacin
Loc.  
Imp.  
11.3  
13  
14.5  
31  
26.5  
33  
91.3  
171  
56  
63  
103.3  
185  
54.3  
106  
34  
57  
391.2  
659  
Cephalexin
Loc.  
Imp.  
8.6  
227  
12.3  
175  
9.7  
14  
82.3  
584  
53.3  
0  
137.3  
318  
55.3  
155  
49  
44  
407.8  
1517  
Metronidazole
Loc.  
Imp.  
8  
18  
17  
23  
21.5  
24  
90.5  
196  
77.5  
88  
153  
241  
137  
194  
25.5  
5  
530  
789  
Fluconazole
Loc.  
Imp.  
9  
9  
27  
3  
31.5  
60  
36.5  
66  
53.5  
66  
84.5  
99  
64.5  
89  
40.5  
59  
347  
451  
Ketoconazole
Loc.  
Imp.  
6.5  
6  
6.5  
9  
10.5  
53  
85.5  
133  
65.5  
76  
77.5  
83  
85.5  
114  
40  
52  
377.5  
526  
Mebendazole
Loc  
Imp  
5.5  
6  
12  
0  
11  
23  
81  
63  
22  
43  
62.5  
269  
42.5  
58  
37.5  
50  
274  
512  
Clarithromycin
Loc.  
Imp.  
7.5  
11  
60  
57  
17  
62  
62  
52  
52  
303  
85  
95  
70.5  
255  
47.5  
8  
401.5  
843  
Terbinafin
Loc.  
Imp.  
10  
23  
35.5  
72  
13.5  
8  
62  
186  
51  
316  
76.5  
298  
50.5  
275  
23  
22  
322  
1200  
  
B. Statistical difference between local and imported anti-infective agents for all products combined   
Mean ± S.E of the total word count 
Variable 
Local agents  Imported agents 
P value 
Description  9.1±0.68 26.8±14.4  0.231 
Indications  21.3±3.6 62.1±21.1  0.068 
Contraindications  19.2±2.5 47.6±15.6  0.084 
Warnings 64.7±4.7 167.7±35.6  0.008* 
Drug Interaction  55.6±4.8 105.5±24.5  0.056 
Dosage and Administration  104.2±12.3 238.3±54.8  0.024* 
Side effects  74.8±8.1 215.2±53.9  0.016* 
Storage 37.9±3.3 46.8±7.4  0.285 
Total  386.8 903.3  0.010* 
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Table 3 Scores of the nine statements in the PPI of local and 
imported anti-infective agents used in the Palestinian market.
Anti- infective agent  Local  Imported 
Amoxicillin 5 6 
Amoxicillin/Clavulanic
acid
5.5 8 
Azithromycin  4.7 4 
Doxycylin 3.3 5 
Trimethoprim / 
Sulfamethoxazole
2.7 4 
Ofloxacine  3.5 4 
Cefuroxime 5 8 
Ciprofloxacin 4 4 
Cephalexine 4.7 5 
Metronidazol  4.5 7 
Fluconazol 4 5 
Mebendazol 4 5 
Clarithromycin  5 5 
Terbinafin 4.5 7 
Ketoconzole  5 4 
Total scores    65.4 81 
The score of each medication represents the number of statement 
in the PPI out of nine tested statements. Significant difference 
exists in the total scores between local and imported products. P 
value for difference of total score = 0.02. * Significant difference.  
Table 4 Scores of the nine statements written in the leaflets 
inserted in the local and imported anti-infective agents. 
Local companies
Statemen
ts
A
n
=
4
B
n
=
8
C
n
 
=
 
1
0
 
D
n
 
=
 
1
4
 
Total
scores
(local
produc
ts)  
n = 36  
Total
scores
(imported
products)
n = 15   
Inactive 
ingredient   
0  0  0  0  0  
6  
Classificati
on   
1  7  10  9  27  
11  
Clinical 
pharmacol
ogy  
0  0  0  0  0  
4  
Pregnancy, 
lactation  
4  8  10  14  36  
15  
Overdose  2  7  5  14  28  15  
Missed 
doses   
1  6  7  13  27  
9  
Duration of 
therapy  
0  8  6  14  28  
15  
Date of 
last 
revision   
0  0  0  0  0  
4  
Not to use 
after expiry 
date  
0  1  0  2  3  2  
Total 
score
8  37  38  66  149  81
Maximal
score
36  72  90  78
4
324  135
Percent 
score
22
.2
%
51
.4
%
42.
2%
8.4
%
46%  60%
The locally produced anti-infective agents are manufactured by 
four companies (A,B,C,D). The score represents number of 
statements written in the PPI. Percentage is calculated by dividing 
total score by the maximal score. 
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